Your browser doesn't support javascript.
loading
Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.
Elmowafy, Ahmed Yahia; El Maghrabi, Hanzada Mohamed; Eldahshan, Khaled Farouk; Refaie, Ayman Fathi; Elbasiony, Mohammed Adel; Matter, Yasser Elsayed; Saleh, Hazem Hamed; Shiha, Gamal Elsayed; Rostaing, Lionel; Bakr, Mohamed Adel.
Afiliación
  • Elmowafy AY; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
  • El Maghrabi HM; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
  • Eldahshan KF; Nephrology Department, Port-Said University, Port Fuad, Egypt.
  • Refaie AF; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
  • Elbasiony MA; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
  • Matter YE; Egyptian Liver Research Institute and Hospital, Mansoura, Egypt.
  • Saleh HH; Internal Medicine Department, Mansoura University, Mansoura, Egypt.
  • Shiha GE; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
  • Rostaing L; Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
  • Bakr MA; Internal Medicine Department, Mansoura University, Mansoura, Egypt.
Int Urol Nephrol ; 51(9): 1639-1647, 2019 Sep.
Article en En | MEDLINE | ID: mdl-31363959
BACKGROUND AND AIMS: New direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV). Our aim was to study the efficacy and safety of this drug regimen among HCV-positive hemodialysis patients. METHODS: This prospective single-center study was performed in the Urology and Nephrology Center, Mansoura University, Egypt. Ninety-six maintenance hemodialysis patients were screened for HCV antibodies. Positive results were found in 46 patients (47.9%). HCV PCR was assessed in all HCV-antibody-positive patients; positive results were found positive for 38 (82%); all patients were HCV genotype 4. Four patients were excluded due to advanced liver cirrhosis, liver malignancy, or metastatic breast cancer. Thirty-four patients were prescribed PTV/OMV/RTV for 3 months to treat HCV. RESULTS: Mean age was 43.2 ± 11.9 years. Most patients were male (67.6%). There was a rapid response to treatment: HCV PCR became negative by 4 weeks after starting treatment. By 12 and 24 weeks post-DAA therapy, there was a sustained viral response (SVR 12, SVR 24) in 100% of patients with improved liver-enzyme levels. CONCLUSION: The PTV/OMV/RTV regimen was safe and effectively treated Egyptian HCV-positive genotype-4 hemodialysis patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Carbamatos / Diálisis Renal / Ritonavir / Hepatitis C Crónica / Compuestos Macrocíclicos / Inhibidores del Citocromo P-450 CYP3A / Anilidas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Int Urol Nephrol Año: 2019 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Carbamatos / Diálisis Renal / Ritonavir / Hepatitis C Crónica / Compuestos Macrocíclicos / Inhibidores del Citocromo P-450 CYP3A / Anilidas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Int Urol Nephrol Año: 2019 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Países Bajos